Program

METABESITY 2019
  • Home
  • About
    • Welcome
    • Target Audience
    • Venue
    • General Information
    • Contact Us
  • Program
    • Full Program
    • Speakers
  • Registration
    • Registration Rates
    • Registration Policies
  • Posters
    • Poster Abstracts
    • Poster Presentations
  • Travel
    • General Travel Information
    • Hotels
    • Transportation
    • Washington, DC
  • Sponsorship
    • Sponsorship Information
    • Sponsors

The program is available below, along with videos of presentations that have been released by the speakers.


​Also  available to download is a PDF program that includes speaker biographies and poster abstracts. ​You may also view speaker biographies and poster abstracts on this website.
Download the Full PDF Program
​PROGRAM
 
Overview

​Metabesity is the constellation of chronic diseases and complications of senescence, all which share metabolic, inflammatory, and other drivers.
​
To the extent that these conditions have common pathogenetic roots, they can be collectively targeted.  The intent of naming this target is to recruit diverse thinking and doing across the landscape of biomedical research, solution development, public policy, commercialization, healthcare integration, and education.  This program is designed to reflect, in microcosm, these constituencies and their contributions, considerations, and challenges.
DAY 1 | TUESDAY, 15 OCTOBER 2019 | 8:30 AM - 5:30 PM
​
THE SCIENCE AND THE SCIENTIFIC INFRASTRUCTURE FOR TARGETING METABESITY
​7:30 AM – 8:30 AM   |  REGISTRATION AND CONTINENTAL BREAKFAST
8:30 AM – 9:45 AM  |  SESSION 1
INTRODUCTION AND ​KEYNOTES
 
The introduction by the Co-chairs sets the stage by articulating the distinctive theme of the conference, on the emerging Science of Metabesity (the focus of Day 1) and its Translation into material, accessible gains in public health (the focus of Day 2).  The Directors of NIA/NIH and of CDER/FDA will anticipate these themes, the former on the basic and translational science conducted and funded by NIA, and the latter on considerations for the important issue of regulatory pathways for prevention and extension of healthy lifespan claims.
​
8:30 AM – 8:40 AM  |  Introduction to Metabesity 
Alexander Fleming, MD, Founder and Executive Chairman of Kinexum, USA and Lawrence Steinman, MD, Professor at Stanford University, USA (Co-chairs)

​8:40 AM – 9:05 AM  |  
Progress and plans at the National Institute on Aging​
Richard Hodes, MD, Director of the National Institute on Aging (NIH), USA

​9:05 AM – 9:30 AM  |  
Challenges in Drug Development for New Preventive Indications
Janet Woodcock, MD, Director of FDA Center for Drug Evaluation and Research, USA

​9:30 AM – 9:45 AM  |  Q&A / Discussion
9:45 AM – 11:15 AM  |  ​SESSION 2
GEROSCIENCE

A panel of leading researchers in geroscience will discuss​ the latest science that encourage intervention against Metabesity to reduce age-related complications.

Moderator:  Richard Hodes, MD, Director of the National Institute on Aging (NIH), USA

Targeting the body’s natural defenses against aging and age-related diseases
David Sinclair, PhD, Co-Director of the Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, USA

New paths from basic research toward clinical trials in geroscience
Matt Kaeberlein, PhD, Director of the Healthy Aging and Longevity Research Institute, University of Washington, USA​

From longevity signatures to longevity interventions
Vadim Gladyshev, PhD, ​Professor of Medicine and Director, Center for Redox Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA
Video Not Released


Interventions at the crossroad of aging and metabolism
Brian Kennedy, PhD, Director of the Centre for Healthy Ageing at the National University Health System, Singapore

Q&A / Discussion - Video Not Released
11:15 AM – 11:35 AM   |  ​MORNING COFFEE BREAK
11:35 AM – 1:05 PM   |  SESSION 3
​CANCER, NEURODEGENERATIVE DISEASES AND CARDIOVASCULAR DISEASES
 
A distinguished panel of researchers and clinicians in geroscience, cancer, neurodegenerative diseases and other chronic diseases of aging (other than diabetes and metabolic diseases, which is the subject of Session 4 below) will discuss the scientific basis for addressing Metabesity and clinical approaches that can be applied.

Moderator: Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences, Pediatrics and Genetics, Stanford, USA -  Co-chair​

Studying aging in humans
Leonard Guarente, PhD, Director of the Paul F. Glenn Center for the Biology of Aging Research at MIT; Co-founder and Chief Scientist of Elysium Health, USA
Video Not Released

Mitochondria and cancer: Potential therapeutic opportunities
Brian Leyland-Jones, MB, BS, PhD, FRACP, FRCPC, VP, Chief Medical Officer and Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR), USA
​Video Not Released

Weight loss for cancer prevention and control
Jennifer Ligibel, MD, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living, Dana-Farber Cancer Institute, USA​
​
Epigenetic resetting of cellular age mediated by nuclear reprogramming: A new paradigm in overcoming aging and aging-associated diseases
Vittorio Sebastiano, PhD, Assistant Professor of Stanford University and Co-Founder of Turn Biotechnologies, USA

Q&A / Discussion - Video Not Released
1:05 PM – 2:00 PM  |  LUNCH AND POSTER PRESENTATIONS ​
2:00 PM – 3:30 PM  |  SESSION 4
DIABETES, OBESITY AND OTHER METABOLIC DISEASES
 
A distinguished panel of diabetologists/endocrinologists will debate the science supporting targeting Metabesity through various modalities, including pharmacology, devices, nutrition, and others. 

Moderator: ​ Jay Skyler, MD, MACP, Professor of Medicine, Pediatrics and Psychology at the University of Miami, USA

Type 2 diabetes is a lifelong disease
John Buse, MD, PhD, Professor of Medicine, Director of Diabetes Care Center of University of North Carolina, USA

T2DM: A cardio metabolic disease linked by insulin resistance
Ralph DeFronzo, MD, Professor of Medicine, University of Texas Health Science Center, San Antonio, USA
Video Not Released

Nonalcoholic steatohepatitis with liver fibrosis (NASH) in patients with DM type II and hyperlipidemia: Is the horse out of the barn?
Brian Harvey, MD, PhD, EVP of Global Liver Institute, USA

Insights on the origins and effects of metabolic damage in type 2 diabetes
​Professor Philip Home, MA DPhil DM FRCP, ​Professor of Diabetes Medicine, University of Newcastle, UK

Q&A / Discussion - Video Not Released
3:30 PM – 3:45 PM  |  ​AFTERNOON BREAK
3:45 PM – 5:15 PM  |  SESSION 5
NUTRITION, LIFESTYLE AND SOCIAL APPROACHES
 
To prevent or delay chronic diseases of aging, it will take more than drugs:  nutrition, exercise, medical devices that alter behaviors, stress relief, socialization, and other modalities will be part of the solution.

Moderator:  Lucy Rose, Founder and President of The Cost of Loneliness Project, USA​​; Former Director of the Division of Drug Advertising and Marketing, CDER, FDA, USA

Nutrigerontology: Using insights into the aging process to provide better nutrition guidelines to address metabolic diseases and to live longer, healthier lives
Kris Verburgh, MD, Researcher at the Free University Brussels, Belgium, and Venture Partner of Longevity Vision Fund
​
Proven Ways to Prolong Quality Lives and Decrease the Cost of Healthcare
Kenneth Cooper, MD, MPH, Founder of The Cooper Institute, USA
​
The cost of loneliness
Lucy Rose, Founder and President of The Cost of Loneliness Project, USA​​; Former Director of the Division of Drug Advertising and Marketing, CDER, FDA, USA
Video Not Released
​
Bringing culinary arts to the health care table
Chef Karl Guggenmos, WACS Global Master Chef, USA

Q&A / Discussion
5:15 PM – 5:30 PM  |  SUMMARY OF DAY 1 AND LOOK AHEAD TO DAY 2
5:30 PM – 7:30 PM   |  COCKTAIL RECEPTION
DAY 2 | WEDNESDAY, 16 OCTOBER 2019 | 8:30 AM - 5:45 PM

TRANSLATION OF METABESITY SCIENCE TO PEOPLE
​   

7:30 AM – 8:30 AM   | ​ REGISTRATION AND CONTINENTAL BREAKFAST
8:30 AM – 9:40 AM  |  SESSION 6
KEYNOTES

The Directors of NHLBI/NIH and of CFSAN/FDA will recapitulate the Science and Translation theme of the conference, in the context of the important progress that has been made in recent decades in prevention, not just treatment, of cardiac and related events, and regulatory considerations for the increasing understanding of the role of nutrition in health and medicine.

8:30 AM – 8:35 AM  |  Day 2 Introduction 
Alexander Fleming, MD, Founder and Executive Chairman of Kinexum, USA and Lawrence Steinman, MD, Professor at Stanford University, USA (Co-chairs)
​
8:35 AM – 9:00 AM  | Translating discovery science for precision prevention​
Gary Gibbons, MD, Director of the National Heart, Lung, and Blood Institute (NHLBI) at NIH, USA

9:00 AM – 9:25 AM  |  FDA’s role in nutrition and chronic disease prevention
Susan Mayne, PhD, Director of FDA Center for Food Safety and Applied Nutrition, USA​
​
9:25 AM – 9:40 AM  |  Q&A / Discussion
9:40 AM – 11:00 AM  |  SESSION 7
CLINICAL DEVELOPMENT ISSUES – CHALLENGES AND OPPORTUNITIES 

Clinical development is another major challenge for targeting Metabesity.  Demonstrating safety and efficacy for prevention and delay could require vast trials over decades based on the classical approach to clinical development.  Some large trials are being performed, e.g. for cardiovascular outcomes and NASH, and aging endpoints might be tractable under designs like the Targeting Aging with Metformin (TAME) trial.  In other cases, pragmatic trials and Real World Evidence may be able to contribute necessary data, while biomarker and surrogate endpoint validation, e.g. using tools like AI, may keep clinical trials manageable.

Moderator: Jay Skyler, MD, MACP, Professor of Medicine, Pediatrics and Psychology at the University of Miami, USA

How to live long to a ripe young age
Nir Barzilai, MD, Director of Institute for Aging Research, Albert Einstein College of Medicine, USA

Considerations of cohort heterogeneity in chronic disease research
William Cefalu, MD, Director of the Division of Diabetes, Endocrinology & Metabolic Diseases, NIDDK/NIH, USA
Video Not Released

The Age-Related Metabolic Program
Michael West, PhD, Founder and CEO of AgeX Therapeutics, USA 

Connecting preclinical discovery and clinical development through AI
Alex Zhavoronkov, PhD, CEO of InSilico Medicine, USA

Q&A / Discussion - Video Not Released
11:00 AM – 11:15 AM  |  ​MORNING COFFEE BREAK
11:15 AM – 11:35 AM  |  SESSION 8
PAYERS AND PROVIDERS
 
Closely related to regulatory labels and clinical evidence is the question of how payers and providers are incentivized with respect to Metabesity approaches.  A traditional insurer may be ambivalent about paying for preventative therapies that may not ‘pay off’ in the form of delayed or avoided chronic illnesses decades later, when a different payer may be involved. A traditional insurer, a managed care provider, a new business model for saving healthcare costs and a single payer government system may have different perspectives on how to achieve extended healthspan.

Fireside Chat between Ed Saltzman, Executive Chairman of Cello Health BioConsulting, and Ryan Walsh, Vice President for Client Services for Real Endpoints, USA​
11:35 AM – 1:05 PM  |  SESSION 9
INDUSTRY:  ESTABLISHED COMPANIES 
 
There is a growing ecosystem of some more established companies, as well as emerging companies, that are targeting Metabesity or watching those that are.  Session 9 will feature the view from Big Pharma, Big Nutrition, Digital Health and others.
​
Moderator:  Joe Cook, Jr.

The overlap of metabolic diseases and early aging... A working hypothesis for changing how we address this space
Joe Cook, Jr., Executive Chairman and President of NuSirt Biopharma; former Chairman and CEO of Amylin, USA

​Novel therapies that are increasing our understanding of disease and leading to changes in drug development

​Stephen Gough, MD, FRCP, SVP Global Chief Medical Officer of Novo Nordisk, Denmark
 
Data and advanced analytics to accelerate the translation of science that matters to patients
Zsolt Bosnyak, MD, PhD
, Global Medical Head of the Insulins Franchise and Diabetes Solution, Sanofi, France
​
Digital health as a platform for improving cardiometabolic health
Bimal Shah, MD, CMO of Livongo Health, USA
​
Aging: An opportunity to nurture vitality
Pietro Antonio Tataranni, MD, Deputy Chief Scientific Officer and Senior Vice President of Life Sciences at PepsiCo R&D, USA

Q&A / Discussion
1:05 PM – 1:50 PM  |  LUNCH AND POSTER PRESENTATIONS ​
1:50 PM – 3:20 PM  |  SESSION 10
INDUSTRY:  EMERGING COMPANIES
 
Joining larger companies in the Metabesity ecosystem are emerging companies that are targeting multiple chronic diseases and longevity based on a variety of approaches.  Leaders of emerging companies will discuss major topics, including drug-facing versus/and consumer-facing business models, the appropriate standards and role of clinical, biomarker and other evidence in regulatory and clinical development and commercialization, and possible contours of the emerging longevity industry.

Moderator:  Ed Saltzman, Executive Chairman, Cello Health BioConsulting, USA
 
Targeting the biology of aging as a new way to prevent and treat aging-related diseases
Joan Mannick, MD, Co-Founder and CMO of resTORbio, USA
Video Not Released

​Nuritas
Nora Khaldi, PhD
, Founder and CSO of Nuritas, Ireland
 
Novel approach to developing therapies for diseases of aging
Sree Kant, Head of Business Development for Life Biosciences, USA
Video Not Released

NuSirt: “Metabesic” therapeutic targets via novel Sirtuin/AMPK co-activation
Michael Zemel, PhD, Founder and Chief Scientific Officer of NuSirt Biopharma, USA
 
Apelin Peptide: An unexpected 20 year journey of the evolutionary longevity agent
John Chan, PhD, CEO of the Apelin Project, USA
Video Not Released

Addressing the metabolic deficit in Alzheimer’s disease
Charles Stacey, MD, President and CEO of Cerecin, USA

Q&A / Discussion - Video Not Released
3:20 PM – 4:05 PM  |  SESSION 11
A VIEW FROM THE CAPITAL MARKETS
 
Funders targeting longevity will share views on investment approaches and a range of business model and strategy topics, which could include drug-facing vs.consumer-facing models, targeting specific diseases vs. mass market targets, organizational structures such as incubator or AI tool platform and subsidiaries targeting specific diseases or hallmarks of aging, how exits might emerge, and what investors want to see from scientists, policy makers, regulators and industry.

Moderator:  Dennis Purcell, Founder and Senior Advisor of Aisling Capital, USA
 
Longevity industry investing requires more advanced and sophisticated analytical methods and de-risking techniques
Kate Batz, Managing Partner of Longevity.Capital, USA

How to fund longevity biotech
James Peyer, PhD, Founder and Managing Partner of Apollo Ventures, USA

Laura Deming, Founder and Partner of The Longevity Fund, USA
Video Not Released

Q&A / Discussion - Video Not Released
4:05 PM – 5:00 PM   |  SESSION 12
FOUNDATIONS, PATIENTS AND GOVERNMENT
 
What can foundations and other not-for-profit entities, patient groups, government, and society at large do, and what are they interested in doing, to promote the delay and prevention of chronic diseases of aging and the extension of health span?  What should the role and prioritization of healthy longevity be in the context of other big challenges and opportunities in coming decades?

Moderator: Jamie Metzl, Author of Hacking Darwin: Genetic Revolution and the Future of Humanity, USA

Leveraging the membership in professional societies to expand the metabesity movement
Karen Tracy, Vice President, Strategic Alliances and Integrated Communications for The Gerontological Society of America (GSA), USA

​What to learn from the UK’s All Party Parliamentary Group on Longevity and an industrial strategy on healthy ageing
Eric Kihlstrom, Strategic Director of Aging Analytics Agency and Secretariat for the UK All-Party Parliamentary Group (APPG) on Longevity, UK​
Video Not Released


Q&A / Discussion
5:00 PM – 5:30 PM  |  SESSION 13
SUMMATION AND A LOOK AHEAD

Moderated panel discussion

    Not on our mailing list? Subscribe to email updates.

Subscribe

Metabesity 2019 Conference Services

Custom Management Group (CMG)
154 Hansen Road, Suite 201
Charlottesville, VA 22911 USA
cmg@custommanagement.com
​+1 434-971-4788
​
custommanagement.com

Conference  services for Metabesity 2019 are provided by Custom Management Group. If you need assistance with abstract submission or registration, please contact CMG by e-mail at cmg@custommanagement.com or by telephone at +1 434-971-4788.
COPYRIGHT METABESITY 2019
  • Home
  • About
    • Welcome
    • Target Audience
    • Venue
    • General Information
    • Contact Us
  • Program
    • Full Program
    • Speakers
  • Registration
    • Registration Rates
    • Registration Policies
  • Posters
    • Poster Abstracts
    • Poster Presentations
  • Travel
    • General Travel Information
    • Hotels
    • Transportation
    • Washington, DC
  • Sponsorship
    • Sponsorship Information
    • Sponsors